<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01852864</url>
  </required_header>
  <id_info>
    <org_study_id>11/H0311/2</org_study_id>
    <nct_id>NCT01852864</nct_id>
  </id_info>
  <brief_title>Degarelix Before Radical Prostatectomy</brief_title>
  <official_title>A Study of the Early Biological Effects of Testosterone Suppression in Prostate Cancer Using Neoadjuvant Degarelix Prior to Radical Prostatectomy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Cambridge</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Cambridge</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The biological effects of castration on prostate cancers will be studies by administration of
      degarelix prior to radical prostatectomy.

      The effects will be studied by analysis of gene expression and immunohistochemistry focusing
      on markers of proliferation and apoptosis of samples taken at the time of radical
      prostatectomy (7 days after administration of degarelix).

      Tumours from patients treated with neo-adjuvant degarelix will be compared with tumours from
      patients who have not been medically castrated.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>July 2011</start_date>
  <completion_date type="Anticipated">December 2015</completion_date>
  <primary_completion_date type="Anticipated">July 2015</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>proliferative index defined by immunohistochemistry for ki67</measure>
    <time_frame>at surgery, 7 days after administration of degarelix</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Gene expression levels measured by microarray</measure>
    <time_frame>At surgery 7 days after degarelix administration</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Degarelix treated group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>240mg degarelix s.c. injection to be administered 7 days prior to radical prostatectomy for high/intermediate risk prostate cancer.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>240mg degarelix s.c. injection</intervention_name>
    <description>7 days prior to radical prostatectomy the patient will have a subcutaneous injection of 240mg degarelix.</description>
    <arm_group_label>Degarelix treated group</arm_group_label>
    <other_name>medical castration</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Intermediate/high risk prostate cancer

          -  Patient eligible for and wanting surgery

        Exclusion Criteria:

          -  Inability to consent

          -  Previous thromboembolism/arrhythmias

          -  contraindication to degarelix or surgery
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Neal, BSc MS FRCS</last_name>
    <role>Study Chair</role>
    <affiliation>Cambridge University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Greg Shaw, MBBS MD FRCS</last_name>
    <phone>01223 331940</phone>
    <email>greg.shaw@cruk.cam.ac.uk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Marie Corcoran</last_name>
    <phone>01223348441</phone>
    <email>marie.corcoran@addenbrookes.nhs.uk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Cambridge University Hopital NHS Trust</name>
      <address>
        <city>Cambridge</city>
        <state>Cambridgeshire</state>
        <zip>CB20QQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Greg Shaw</last_name>
    </contact>
    <investigator>
      <last_name>David Neal, MS FRCS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>December 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 6, 2013</study_first_submitted>
  <study_first_submitted_qc>May 9, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 14, 2013</study_first_posted>
  <last_update_submitted>December 15, 2014</last_update_submitted>
  <last_update_submitted_qc>December 15, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 16, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Cambridge</investigator_affiliation>
    <investigator_full_name>Greg Shaw</investigator_full_name>
    <investigator_title>Clinical Lecturer in Urology</investigator_title>
  </responsible_party>
  <keyword>Prostate cancer</keyword>
  <keyword>testosterone</keyword>
  <keyword>castration</keyword>
  <keyword>degarelix</keyword>
  <keyword>proliferation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Testosterone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

